التفاصيل البيبلوغرافية
| العنوان: |
Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor. |
| المؤلفون: |
Fanous, Matthew M., Gianos, Eugenia, Sperling, Laurence S., Mintz, Guy L., Majure, David T., Hirsh, Benjamin J. |
| المصدر: |
Journal of Clinical Lipidology; Jul2021, Vol. 15 Issue 4, p579-583, 5p |
| مصطلحات موضوعية: |
HEART transplantation, CARDIOMYOPATHIES, HEPATITIS C, ANTIVIRAL agents, DRUG interactions |
| مستخلص: |
• Statins in HCV heart transplant recipients may be avoided due to drug interactions. • Nonstatin therapy for prevention of CAV has not been well studied. • PCSK9 inhibitors appear safe among recipients of hepatitis C virus positive donors. • Early PCSK9 inhibition may be beneficial for recipients of hepatitis C virus donors. Although statin therapy is a primary treatment to prevent cardiac allograft vasculopathy (CAV), its use may be delayed due to pharmacologic interactions in the early post-transplant period among heart transplant (HT) recipients with hepatitis C virus positive (HCV+) donors. Further examination of the possible benefits of early, nonstatin lipid-lowering therapies (LLT), such as PCSK9 inhibitors (PCSK9i), among this specific subset of transplant recipients is therefore becoming increasingly important. We report a 60-year-old man who received a HT from a HCV+ donor for end-stage ischemic cardiomyopathy. In the early post-transplant period, there was concern for drug-drug interactions between statin, immunosuppressant, and direct acting antiviral (DAA) therapy. In addition, prior to transplant, he reported statin-associated muscle symptoms in response to multiple statins, which persisted despite attempts to re-challenge and use an every-other-day dosing strategy. Therefore, the patient was started on PCSK9i therapy after transplantation and while receiving curative DAA therapy for HCV. As the number of HT recipients of HCV+ donors continue to rise, investigation into the safety and benefits of early use of PCSK9i for the reduction of CAV and improved cardiovascular and mortality outcomes should be pursued. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Lipidology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
